End-stage Renal Disease Clinical Trial
— LDCOfficial title:
Implementation of the Live Donor Champion Program
Verified date | January 2024 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Live Donor Champion Program is a clinical education program offered to patients placed on the waitlist for kidney transplantation at the Johns Hopkins Comprehensive Transplant Center. The goal of the program is to increase patient knowledge regarding end stage renal disease, kidney transplantation, and live kidney donation and to help patients identify potential live kidney donors. Patients are encouraged to bring family and friends to participate in the program and act as advocates on their behalf. These friends and family members are labeled "live donor champions" and work to assist the patient in spreading awareness about end stage renal disease, kidney transplantation, and live kidney donation. The objectives of this project are to pilot-test and optimize strategies for the dissemination of the Live Donor Champion program in the clinical transplant center setting. The goals of the study are to develop an implementation protocol for centers who want to establish a live donor champion program at their institution.
Status | Active, not recruiting |
Enrollment | 111 |
Est. completion date | December 2024 |
Est. primary completion date | November 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Waitlist Candidates Inclusion Criteria: - Kidney transplant candidates aged=18 added to the waitlist in the last year with no potential live donors are eligible. - If there is an individual willing to donate, but the candidate is unwilling to consider this option or this particular individual, the candidate is eligible for the trial and may still benefit from identification of new donors or increased comfort accepting donation from others. - Participants at University or University of Alabama must speak English. Participants at Northwestern University must speak English or Spanish. Exclusion Criteria: - Candidates with live donors currently under evaluation for donation will be excluded. - Those with a previous kidney transplant will be excluded Live Donor Champions Inclusion Criteria - aged=18 - English-speaking - Be a "Live Donor Champion" (a friend, family member or community member willing to advocate for the wait-listed patient). Exclusion Criteria - <18, not English-speaking LDC Administrators Inclusion Criteria - aged=18 - English-speaking - Performed tasks related to implementing the LDC program Exclusion Criteria - <18, not English-speaking, and no affiliation with implementing the LDC program |
Country | Name | City | State |
---|---|---|---|
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Washington University in Saint Louis | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acceptability - Implementation Outcome | Acceptability is the perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory. Acceptability will be measured qualitatively using an adapted Consolidated Framework for Implementation Research (CFIR) instrument. This instrument will be used during interviews with key stakeholders. | within 2 years of enrollment | |
Primary | Adoption - Implementation Outcome | Adoption is defined as the intention or action to employ an innovation or practice. Adoption will be measured qualitatively using an adapted Consolidated Framework for Implementation Research (CFIR) instrument. This instrument will be used during interviews with key stakeholders. | within 2 years of enrollment | |
Primary | Appropriateness - Implementation Outcome | Appropriateness is a qualitative measure of the perceived fit, relevance, or compatibility of the innovation for a given setting, provider, or consumer; and/or perceived fit of the innovation to address a particular issue. We will measure program appropriateness using an adapted Consolidated Framework for Implementation Research (CFIR) instrument. This instrument will be used during interviews with key stakeholders. | within 2 years of enrollment | |
Primary | Cost - Implementation Outcome | Cost (incremental or implementation cost) is the cost impact of an implementation effort. Implementation cost will be assessed by estimations made during observational sessions of the intervention. | within 2 years of enrollment | |
Primary | Feasibility - Implementation Outcome | Feasibility is defined as the extent to which a new treatment, or an innovation, can be successfully used or carried out within a given agency or setting. Feasibility will be assessed qualitatively using an adapted Consolidated Framework for Implementation Research (CFIR) instrument. This instrument will be used during interviews with key stakeholders. | within 2 years of enrollment | |
Primary | Fidelity - Implementation Outcome | Fidelity is defined as the degree to which an intervention was implemented as prescribed in the original protocol or as it was intended by the developers. Fidelity will be qualitatively assessed using an adapted Consolidated Framework for Implementation Research (CFIR) instrument. This instrument will be used during interviews with key stakeholders. | within 2 years of enrollment | |
Primary | Penetration - Implementation Outcome | Penetration is the integration of a practice within a setting or subsystem. Penetration of the LDC program within our two sites will be measured by calculating the number of eligible persons who use a service, divided by the total number of eligible. | within 2 years of enrollment | |
Primary | Sustainability - Implementation Outcome | Sustainability is defined as the extent to which a newly implemented treatment is maintained or institutionalized within a service setting's ongoing, stable operations. Sustainability will be qualitatively assessed using an adapted Consolidated Framework for Implementation Research (CFIR) instrument. This instrument will be used during interviews with key stakeholders. | within 2 years of enrollment | |
Secondary | Live donor kidney transplantation | Live donor kidney transplantation within one year of enrollment into the study will be collected/identified through electronic medical record system. | within 1 year of enrollment | |
Secondary | Live Donor Inquiries | Live Donor Inquiries on behalf of candidates will be collected/identified through electronic medical record system. | within 1 year of enrollment | |
Secondary | Knowledge of live donation and kidney transplantation | Knowledge of live donation of transplant candidates will be collected during the survey. | within 6 months of enrollment | |
Secondary | Comfort initiating conversations | Comfort initiating conversations with others about live donation will be collected during the survey. | within 6 months of enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04087213 -
Study of HemoCareā¢ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD
|
N/A | |
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Completed |
NCT02237521 -
The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease
|
N/A | |
Withdrawn |
NCT01691196 -
Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
|
||
Completed |
NCT01394341 -
Liraglutide Treatment to Patients With Severe Renal Insufficiency
|
Phase 4 | |
Active, not recruiting |
NCT00247507 -
The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT00307463 -
Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation
|
Phase 4 | |
Recruiting |
NCT00155363 -
Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis
|
Phase 4 | |
Completed |
NCT00234156 -
The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers
|
N/A | |
Completed |
NCT00586131 -
Arterial pH and Total Body Nitrogen Balances in APD
|
Phase 4 | |
Active, not recruiting |
NCT05027074 -
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
|
Phase 2 | |
Recruiting |
NCT04575077 -
The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
|
||
Enrolling by invitation |
NCT05001009 -
Goals of Care Conversations Study
|
N/A | |
Completed |
NCT01756508 -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
|
Phase 2 | |
Recruiting |
NCT03862859 -
The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis
|
Phase 4 | |
Terminated |
NCT03661229 -
Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device
|
N/A | |
Completed |
NCT03288922 -
Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF
|
N/A | |
Completed |
NCT02360748 -
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients
|
N/A | |
Completed |
NCT02572882 -
Gut Microbiome and p-Inulin in Hemodialysis
|
N/A |